HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

about

Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia

P2860

Q59137904-9AB01DFD-409D-4594-9A82-3BB54A22374D

P2860

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

Item

http://www.wikidata.org/entity/Q47114002

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

@en

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

@nl

type

Item

label

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

@en

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

@nl

prefLabel

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

@en

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

@nl

P1476

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

@en

P2093

Andrew L Kung

http://www.w3.org/2001/XMLSchema#string

James E Bradner

http://www.w3.org/2001/XMLSchema#string

Jen-Chieh Tseng

http://www.w3.org/2001/XMLSchema#string

Jun Qi

http://www.w3.org/2001/XMLSchema#string

Naoya Mimura

http://www.w3.org/2001/XMLSchema#string

Ralph Mazitschek

http://www.w3.org/2001/XMLSchema#string

Teru Hideshima

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis of caspase-7 inhibition by XIAP

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.

Specific activity of class II histone deacetylases in human breast cancer cells

Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer

The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation.

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells.

P304

80109-80123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.19019

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

P577

2017-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29113288

http://www.w3.org/2001/XMLSchema#string

P932

5655183

http://www.w3.org/2001/XMLSchema#string

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

about

P2860

P2860

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932